Naslov
Demographic, laboratory and clinical characteristics of newly diagnosed HCV patients during COVID-19 pandemic

Autori
Radmanić, Leona ; Šimičić, Petra ; Papić, Neven ; Kurelac, Ivan ; Židovec Lepej, Snježana ; Vince, Adriana

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
3rd South-East European Conference on Travel, Tropical, Migration Medicine and HIV and the 4th Croatian Conference on Travel, Tropical, Migration Medicine and HIV - Book of Abstracts / - , 2021, 32-32

Skup
3rd South-East European Conference on Travel, Tropical, Migration Medicine and HIV and the 4th Croatian Conference on Travel, Tropical, Migration Medicine and HIV (3rd SEE CTM & HIV 2021)

Mjesto i datum
Zadar, Hrvatska, 16.09.2021. - 19.09.2021

Vrsta sudjelovanja
Poster

Vrsta recenzije
Domaća recenzija

Ključne riječi
hepatitis C virus ; COVID-19 ; fibrosis ; genotype ; subtype

Sažetak
The aim of this study was to analyze the demographic, laboratory and clinical characteristics of newly diagnosed HCV patients during COVID-19 pandemic at the University Hospital for Infectious Diseases (UHID). From January 2020 to June 2021 there were 75 patients newly diagnosed with HCV at UHID. The stage of fibrosis (F1-F4) was determined by elastography (FibroScan) before antiviral treatment. HCV RNA was quantified by real-time PCR (Abbott RealTime HCV). HCV genotypes and subtypes were determined by PCR and reverse hybridization (INNO-LiPA HCV Genotyping) method. The results were analysed by descriptive statistical methods. A total of 75 HCV positive adults were analysed (64% males, 36% females, median age 47 years, range 21-88 years) (Figure 1). Genotype 1 was detected in 1 patient(1.3%), subtype 1a in 17 patients (22.7%), 1b in 21 patients (28%), subtype 2b in 1 patient(1.3%), subtype 3a in 29 patients (38.7%) and genotype 4 in 1 (1.3%) patient, while 5 patients were undetermined (6.7%) (Figure 2). Prior to treatment initiation, F1 fibrosis stage was determined in 32% of patients, F2 in 20% of patients, F3 in 8% of patients, while 28% of patients had F4 stage (median 8.05, IQR 3.3-60.4 kPa). Median viremia was 1 965 992 IU/ml (range 1 012-11, 937, 251 IU RNA HCV/mL). The majority of newly diagnosed HCV patients during COVID-19 pandemic were middle aged and male. Genotype 1 was the most prevalent followed by subtype 3a. Interestingly, subtype 1b was more common than 1a. Prior to treatment initiation, the most common fibrosis stages were F1 and F4.

Izvorni jezik
Engleski

Znanstvena područja
Biologija, Interdisciplinarne prirodne znanosti, Temeljne medicinske znanosti, Kliničke medicinske znanosti

POVEZANOST RADA